Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Cash Flow: 2014-2024

Historic Net Cash Flow for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to -$28.7 million.

  • Viking Therapeutics' Net Cash Flow rose 929.28% to $66.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year increase of 280.10%. This contributed to the annual value of -$28.7 million for FY2024, which is 251.70% down from last year.
  • Viking Therapeutics' Net Cash Flow amounted to -$28.7 million in FY2024, which was down 251.70% from $18.9 million recorded in FY2023.
  • Viking Therapeutics' Net Cash Flow's 5-year high stood at $20.7 million during FY2020, with a 5-year trough of -$28.7 million in FY2024.
  • Moreover, its 3-year median value for Net Cash Flow was $10.5 million (2022), whereas its average is $247,000.
  • In the last 5 years, Viking Therapeutics' Net Cash Flow surged by 483.07% in 2022 and then crashed by 251.70% in 2024.
  • Yearly analysis of 5 years shows Viking Therapeutics' Net Cash Flow stood at $20.7 million in 2020, then tumbled by 113.24% to -$2.7 million in 2021, then soared by 483.07% to $10.5 million in 2022, then skyrocketed by 79.81% to $18.9 million in 2023, then tumbled by 251.70% to -$28.7 million in 2024.